CytomX Therapeutics, Inc. (CTMX)
Develops cancer-fighting drugs that activate only when they reach tumors.
$3.22-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+37.0%
The outlook
CTMX trades at $3.22, well below both its 50- and 200-day moving averages and sitting near the lower end of its 52-week range. Analyst coverage leans bullish on valuation, with an average price target implying significant upside from current levels, though the overall sentiment scores bearish. The stock's position in its recent trend and low StockGlow score suggest caution among investors despite optimistic analyst targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +288% vs current price
Analyst price target
~12-month · 8 analysts$12.50average target+288.2% vs now
Now $3.22
Low $6.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$701.0M
52-wk high
$8.21
52-wk low
$1.72
50-day avg
$3.44
200-day avg
$4.19
Trailing P/E
—